On May 18, 2016 Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, reported that in partnership with its collaborators it will present key clinical updates on its investigational products JCAR014, JCAR015 and JCAR017 at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2016 in Chicago, Illinois from June 3-7 (Press release, Juno, MAY 18, 2016, View Source;p=irol-newsArticle&ID=2169503 [SID:1234512547]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JCAR014, JCAR015 and JCAR017 are chimeric antigen receptor (CAR) T cell product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL). New data from the ongoing JCAR014 trial in patients with relapsed or refractory ALL, NHL, or CLL will be presented, with increased patient numbers and longer duration of follow-up compared to previous presentations. Investigators will also present updated data from the ongoing trial of JCAR017 in children with relapsed or refractory ALL, including the first experience of patients treated with the pre-conditioning regimen of fludarabine/cyclophosphamide. Ongoing data from the phase I experience of JCAR015 will also be presented, including in adult patients with relapsed or refractory ALL.

Key data presentations at ASCO (Free ASCO Whitepaper) include:
JCAR014
Rate of Durable Complete Response in ALL, NHL, and CLL After Immunotherapy with Optimized Lymphodepletion and Defined Composition CD19 CAR-T Cells
Oral abstract 102
Presenter: Cameron J. Turtle, MBBS, Ph.D. of the Fred Hutchinson Cancer Research Center
Date: Saturday, June 4, 2016: 8:48 a.m. Central Time
Location: Hall D1

JCAR017
Prolonged Functional Persistence of CD19 CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Determines Durability of MRD-Negative ALL Remission
Presenter: Rebecca Gardner, M.D. of Seattle Children’s Research Institute
Date: Sunday, June 5, 2016: 8:00 – 11:30 a.m. Central Time
Location: Hall A, Poster Board #370

JCAR015
Impact of Disease Burden on Long-Term Outcome of 19-28z CAR Modified T Cells in Adult Patients with Relapsed B-ALL
Presenter: Jae H. Park, M.D. of Memorial Sloan Kettering Cancer Center
Date: Saturday, June 4, 2016: 4:00 p.m. Central Time
Location: Arie Crown Theatre

Updated Results: Phase I Trial of Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL Following Initial Purine Analog-Based Therapy
Presenter: Mark B. Geyer, M.D., Department of Medicine, Memorial Sloan Kettering Cancer Center
Date: Monday, June 6, 2016: 8:00 – 11:30 a.m. Central Time
Location: Hall A, Poster Board #82

About Juno’s Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) Technologies
Juno’s CAR and TCR technologies genetically engineer T cells to recognize and kill cancer cells. Juno’s CAR T cell technology inserts a gene for a particular CAR into the T cell, enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface. Juno’s TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. When either type of engineered T cell engages the target protein on the cancer cell, it initiates a cell-killing response against the cancer cell. JCAR014, JCAR015, and JCAR017 are investigational product candidates and their safety and efficacy have not been established.